The relative efficiency of time-to-threshold and rate of change in longitudinal data - Wikidata - awgldk - TriplyDB

The relative efficiency of time-to-threshold and rate of change in longitudinal data

The relative efficiency of time-to-threshold and rate of change in longitudinal data

http://www.wikidata.org/entity/Q33893531

about

Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement.Subsets of a large cognitive battery better power clinical trials on early stage Alzheimer's disease.Measuring clinical progression in MCI and pre-MCI populations: enrichment and optimizing clinical outcomes over time Cognitive/Clinical Endpoints for Pre-Dementia AD Trials.Impact of PCA strategies on pain intensity and functional assessment measures in adults with sickle cell disease during hospitalized vaso-occlusive episodes.Disease progression model in subjects with mild cognitive impairment from the Alzheimer's disease neuroimaging initiative: CSF biomarkers predict population subtypes Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies

P2860

Q26801657-60FA9183-41AB-43AE-BB69-C00723DBFB7D Q27006831-10FFA280-70DA-4DBC-9BD8-CD760B26BF59 Q30971403-0C848543-EC32-4983-999A-98B68682583B Q31147579-D2D27DBA-C8F3-4266-9029-448615FE9727 Q34541727-CD9BD0D6-EF80-4429-81AA-C03119BD4388 Q36424833-AFD78091-872C-4895-95F7-A2F3581FB155 Q36463140-D9FA1765-C9D8-40D9-A34B-A60E99223277 Q36497041-9B979E76-F118-47CE-88F8-85CDAE6AACB8 Q36562471-A677C510-578C-4C25-BC7E-C517EA4F7CEE Q36574825-4DA1D475-1D73-4737-91F6-97C690C813FF Q37068194-03562DE8-1AE9-4632-88FE-027D262CDDEC Q37291510-CF871711-0671-4945-AB6A-C23FE9E22DED

P2860

The relative efficiency of time-to-threshold and rate of change in longitudinal data

http://www.wikidata.org/entity/Q33893531

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

The relative efficiency of time-to-threshold and rate of change in longitudinal data

@ast

The relative efficiency of time-to-threshold and rate of change in longitudinal data

@en

type

label

The relative efficiency of time-to-threshold and rate of change in longitudinal data

@ast

The relative efficiency of time-to-threshold and rate of change in longitudinal data

@en

prefLabel

The relative efficiency of time-to-threshold and rate of change in longitudinal data

@ast

The relative efficiency of time-to-threshold and rate of change in longitudinal data

@en

P1433

Q33893531-9F83A28A-F3FC-48A9-A673-E6E325ECCB84

P1476

Q33893531-32CC1412-E9CE-4CDF-9B82-0FF58D0906D8

P2093

Q33893531-09135306-D1E8-44C3-A340-808D0E10BE59

Q33893531-0CB383C9-24BF-43BC-9358-8884B0D0EF3C

Q33893531-7CA1AC57-2406-495A-ADE8-C55E05994155

Q33893531-8C1CC197-431D-46CE-8DCA-2D3A8EFE7F45

Q33893531-BFD459F3-D070-4A17-AD07-005AC71D4D3E

Q33893531-CF1D695E-E567-4879-A181-BBDB5D12F521

Q33893531-D7F4A78C-0F34-495C-95EC-845E96E91299

P2860

Q33893531-02FB4509-0BF7-4A63-AAA3-8AEBD3FBE691

Q33893531-0C7ED8D2-8AE0-471F-9E50-3597C41FBB1D

Q33893531-129E4B10-FFF1-4085-9D6E-C661E3510F04

Q33893531-222F2BF6-C344-4402-A45F-19323F79EA14

Q33893531-34C5C313-1B16-4E0F-9D88-5BA267CAB165

Q33893531-3C36E2CA-ABB8-4A8D-9BB3-C52CBFBDA4EC

Q33893531-446A0A0B-BAB3-43B9-8A60-47878731A4FB

Q33893531-6A793B77-65EC-4740-AA65-DE916084BD04

Q33893531-840E968C-6800-42B3-B142-E8CF1E0CC034

Q33893531-9FB0AF1E-E87F-4CBC-83F4-8A7F2E2A5E08

P304

Q33893531-07DA16D0-F4E3-406A-800B-38EC9FBA8C93

P31

Q33893531-F0706286-1E02-4063-9CE3-937625555032

P356

Q33893531-9C1BB740-26AA-40D5-9675-77ECBE2548F7

P407

Q33893531-6EFE5CC3-B55C-495E-83C1-C8B83ADB4151

P433

Q33893531-51239545-F8B8-4ACB-8D12-4D3CB4B50735

P478

Q33893531-31565414-53FD-4A8F-99D8-EE86C66AC1D1

P50

Q33893531-D876F2C2-CFFE-4FD5-A71A-DB22456FF950

Q33893531-FA4EF628-EDD8-4127-A8D6-1D9CDE4E98F9

P577

Q33893531-EA470399-E742-4A2E-881A-D1447FB0A758

P5875

Q33893531-8AAA6FF0-FFC0-4C28-891D-EAB6E1A01480

P698

Q33893531-99346662-EABC-4D29-8A14-937DD8B8A9D9

P932

Q33893531-C62658B3-BC84-426A-B0DD-000CFCBEC053

P356

J.CCT.2011.04.007

P1433

Contemporary Clinical Trials

P1476

The relative efficiency of time-to-threshold and rate of change in longitudinal data

@en

P2093

A C Gamst

http://www.w3.org/2001/XMLSchema#string

L Beckett

http://www.w3.org/2001/XMLSchema#string

M W Weiner

http://www.w3.org/2001/XMLSchema#string

P Aisen

http://www.w3.org/2001/XMLSchema#string

R C Petersen

http://www.w3.org/2001/XMLSchema#string

R G Thomas

http://www.w3.org/2001/XMLSchema#string

R Xu

http://www.w3.org/2001/XMLSchema#string

P2860

Random-effects models for longitudinal data

Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study

Longitudinal data analysis for discrete and continuous outcomes

Continuous, categorical, and time to event cocaine use outcome variables: degree of intercorrelation and sensitivity to treatment group differences.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small.

Prostate-specific antigen (PSA) alone is not an appropriate surrogate marker of long-term therapeutic benefit in prostate cancer trials.

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

P304

685-693

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CCT.2011.04.007

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

Michael Donohue

Alzheimer's Disease Neuroimaging Initiative

P577

2011-04-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51110209

http://www.w3.org/2001/XMLSchema#string

P698

21554992

http://www.w3.org/2001/XMLSchema#string

P932

3148349

http://www.w3.org/2001/XMLSchema#string